SCHEMBL640436

SCHEMBL640436

O=C1N=c2ccccc2=N1.[N]

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 2/20 0.33
TDP2 O95551 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CDC25B P30305 2/20 0.33
MAOA P21397 3/20 0.32
MAOB P27338 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CES2 O00748 1/20 0.32
TERT O14746 1/20 0.32
NPC1 O15118 1/20 0.32
PLIN1 O60240 1/20 0.32
S1PR4 O95977 1/20 0.32
LMNA P02545 1/20 0.32
PLA2G1B P04054 1/20 0.32
BCHE P06276 1/20 0.32
POLB P06746 1/20 0.32
PTPRC P08575 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL37950 0.97 MEN1 (0.35) APAF1TDP2MEN1KMT2ACDC25B
Bromide SCHEMBL28523892 0.94 APAF1 (0.33) APAF1TDP2MEN1KMT2ACDC25B
Water SCHEMBL11357123 0.94 APAF1 (0.33) APAF1TDP2MEN1KMT2ACDC25B
Hydrochloric Acid SCHEMBL4647777 0.94 APAF1 (0.33) APAF1TDP2MEN1KMT2ACDC25B
SCHEMBL31241401 0.94 APAF1 (0.33) APAF1TDP2MEN1KMT2ACDC25B
Dioxane SCHEMBL3787148 0.82 SMN1; SMN2 (0.41) APAF1TDP2MEN1KMT2ANPC1
SCHEMBL317892 0.78 MAPT (0.40) APAF1TDP2MEN1KMT2ACDC25B
Methylglyoxal SCHEMBL28580135 0.77 ALDH1A1 (0.36) KMT2AKDM4ECES2NPC1LMNA
Acrylamide SCHEMBL16585912 0.75 TSHR (0.44) MEN1KMT2AKDM4EPOLBMAPT
SCHEMBL21359837 0.75 MAPT (0.38) APAF1TDP2MEN1KMT2ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
CN-101528712-B Substituted benzimidazolone derivatives, medicaments containing them and the use thereof ABBOTT GMBH & CO KG 2013-10-30 CN disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
CN-101528712-A Substituted benzimidazolone derivatives, medicaments containing them and the use thereof ABBOTT GMBH & CO KG (DE) 2009-09-09 CN disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 APAF1 2787/4885TDP2 1001/4885MEN1 3011/4885
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A APAF1 2259/4885TDP2 2925/4885MEN1 43/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A APAF1 2259/4885TDP2 2925/4885MEN1 43/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 APAF1 2787/4885TDP2 1001/4885MEN1 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.